Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
306
Operating loss of ¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending December 20262 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥6 million
Operating profit¥-306 million
Net income¥-307 million
Selling, general and administrative expenses¥198 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Research and development costs¥112 million
- Selling, general and administrative expenses¥198 million
- Year-on-year increase in selling, general and administrative expenses¥7 million
New initiatives
- License agreement with MAAB Pharma Limited for manufacturing and marketing rights in China, and launch of sales
- Initiatives aimed at local production of Sancuso® in China
- Animal testing and cell-model evaluation of SP-04 for taxane-induced peripheral neuropathy
- SP-05 Phase II clinical trial in Japan scheduled to begin in the second half of fiscal 2026
- Joint research and commercialization studies involving nucleic acid medicines, RNA editing, antibody modification, and functional fluorescent probes
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Net Sales | ¥6 million |
| Operating profit | ¥-306 million |
| Net income | ¥-307 million |
| Selling, general and administrative expenses | ¥198 million |
| Breakdown of Factors Affecting the Change | Research and development costs ¥112 million, Selling, general and administrative expenses ¥198 million, Year-on-year increase in selling, general and administrative expenses ¥7 million |
| New initiatives | License agreement with MAAB Pharma Limited for manufacturing and marketing rights in China, and launch of sales, Initiatives aimed at local production of Sancuso® in China, Animal testing and cell-model evaluation of SP-04 for taxane-induced peripheral neuropathy, SP-05 Phase II clinical trial in Japan scheduled to begin in the second half of fiscal 2026, Joint research and commercialization studies involving nucleic acid medicines, RNA editing, antibody modification, and functional fluorescent probes |
Items this document does not state (23)
Ordinary incomeGross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.While revenue was recorded mainly from sales of Episil® products, the Company recorded ¥112 million in research and development expenses, primarily for the expansion of Dalvance® indications, animal testing of SP-04, and investment in new development candidates. Selling, general and administrative expenses also totaled ¥198 million. Sancuso® generated no product sales in the first quarter due to the transfer to a Chinese sales partner, and no income from the installment payment under the license agreement has yet been recognized.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.